FI4214202T3 - Cdk4-estäjän kiinteät muodot - Google Patents

Cdk4-estäjän kiinteät muodot Download PDF

Info

Publication number
FI4214202T3
FI4214202T3 FIEP21783049.6T FI21783049T FI4214202T3 FI 4214202 T3 FI4214202 T3 FI 4214202T3 FI 21783049 T FI21783049 T FI 21783049T FI 4214202 T3 FI4214202 T3 FI 4214202T3
Authority
FI
Finland
Prior art keywords
cancer
crystalline form
ppm
values
wavenumber
Prior art date
Application number
FIEP21783049.6T
Other languages
English (en)
Finnish (fi)
Inventor
Wesley Dewitt Clark
Judith Gail Deal
Brian Matthew Samas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of FI4214202T3 publication Critical patent/FI4214202T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP21783049.6T 2020-09-15 2021-09-13 Cdk4-estäjän kiinteät muodot FI4214202T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078636P 2020-09-15 2020-09-15
US202163240268P 2021-09-02 2021-09-02
PCT/IB2021/058320 WO2022058871A1 (en) 2020-09-15 2021-09-13 Solid forms of a cdk4 inhibitor

Publications (1)

Publication Number Publication Date
FI4214202T3 true FI4214202T3 (fi) 2025-04-25

Family

ID=78000744

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21783049.6T FI4214202T3 (fi) 2020-09-15 2021-09-13 Cdk4-estäjän kiinteät muodot

Country Status (17)

Country Link
US (1) US12570641B2 (enExample)
EP (2) EP4578450A3 (enExample)
JP (2) JP7260606B2 (enExample)
KR (1) KR20230069983A (enExample)
CN (1) CN116507620B (enExample)
AU (1) AU2021345531B2 (enExample)
DK (1) DK4214202T3 (enExample)
ES (1) ES3022913T3 (enExample)
FI (1) FI4214202T3 (enExample)
HU (1) HUE070846T2 (enExample)
MX (1) MX2023003054A (enExample)
PL (1) PL4214202T3 (enExample)
PT (1) PT4214202T (enExample)
SI (1) SI4214202T1 (enExample)
TW (2) TWI809503B (enExample)
WO (1) WO2022058871A1 (enExample)
ZA (1) ZA202303655B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3061133T3 (en) 2019-08-26 2026-03-31 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
MX2023003054A (es) 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
WO2023100070A1 (en) * 2021-12-02 2023-06-08 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
US20260027087A1 (en) 2022-07-29 2026-01-29 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
KR20250054814A (ko) * 2022-09-05 2025-04-23 티와이케이 메디슨즈, 인코포레이티드 Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
CN121368483A (zh) 2023-06-02 2026-01-20 辉瑞公司 雌激素受体降解剂与cdk4抑制剂的组合
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025104624A1 (en) 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol
WO2025202900A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
WO2025202871A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
TW201105669A (en) 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
CN105111191B (zh) 2015-07-21 2018-06-08 上海皓元生物医药科技有限公司 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途
SG11201900328WA (en) * 2016-07-13 2019-02-27 Jason Marineau Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112019002610A2 (pt) 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
MD3784664T2 (ro) 2018-04-26 2025-06-30 Pfizer Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
MX2023003054A (es) 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.

Also Published As

Publication number Publication date
TW202334125A (zh) 2023-09-01
JP7291839B2 (ja) 2023-06-15
JP7260606B2 (ja) 2023-04-18
US20230357211A1 (en) 2023-11-09
EP4214202A1 (en) 2023-07-26
JP2022049005A (ja) 2022-03-28
CA3195063A1 (en) 2022-03-24
HUE070846T2 (hu) 2025-07-28
PL4214202T3 (pl) 2025-05-19
AU2021345531A1 (en) 2023-04-20
EP4214202B1 (en) 2025-02-26
SI4214202T1 (sl) 2025-05-30
CN116507620B (zh) 2025-11-18
EP4578450A2 (en) 2025-07-02
JP2022186995A (ja) 2022-12-15
AU2021345531B2 (en) 2024-02-29
EP4578450A3 (en) 2025-07-16
DK4214202T3 (da) 2025-03-31
BR112023004713A2 (pt) 2023-04-18
MX2023003054A (es) 2023-04-05
TWI809503B (zh) 2023-07-21
WO2022058871A1 (en) 2022-03-24
CN116507620A (zh) 2023-07-28
ZA202303655B (en) 2024-09-25
ES3022913T3 (en) 2025-05-29
KR20230069983A (ko) 2023-05-19
PT4214202T (pt) 2025-04-11
TW202216698A (zh) 2022-05-01
US12570641B2 (en) 2026-03-10

Similar Documents

Publication Publication Date Title
JP2022049005A5 (enExample)
JP2022186995A5 (enExample)
HRP20100166T1 (hr) Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
KR102534266B1 (ko) 헤테로환형 유도체 및 이의 용도
FI2534153T4 (fi) 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
JP2015512942A5 (enExample)
MX2010001745A (es) Imidazoles fusionados para el tratamiento del cancer.
FI3694863T3 (fi) Lorlatinibin vapaan emäksen hydraatin kidemuoto
JP2012526808A5 (enExample)
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
JP2024503235A5 (enExample)
HRP20171895T1 (hr) Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline
KR101129088B1 (ko) N-[6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일]-2-메틸-4'-(트리플루오로메톡시)[1,1'-비페닐]-3-카르복스아미드의 염
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
HRP20171041T1 (hr) Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže
JP2016504325A5 (enExample)
JP2015502371A5 (enExample)
WO2014152566A3 (en) Methods of synthesizing substituted purine compounds
HRP20140409T1 (hr) Derivat imidazola sa strukturom prolinskog prstena
FI3317264T3 (fi) (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola